Lapatinib
Generated by NIH 3D workflows using data provided by
Kzoghebi
Created:
2/17/19
Submitted:
3/6/23
Published:
3/6/23
Select an image below to view
Category
Description
Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
